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S U M M A R Y
Objectives: To investigate the incidence rates of candidemia in hospitalized patients and to identify
differences in risk factors of patients with Candida albicans and non-C. albicans and with Candida
guilliermondii and non-C. guilliermondii candidemia.
Methods: Non-immunosuppressed, non-neutropenic inpatients with candidemia diagnosed after
admission were included in this retrospective observational study at a tertiary academic hospital in
China.
Results: During the study period (January 2009 to December 2011), 238 eligible patients had candidemia
episodes with an incidence rate 5.4%. Of these patients, 29.8% had candidemia due to C. albicans, 27.7%
due to C. parapsilosis, and 16.4% due to C. guilliermondii. Diabetes was a signiﬁcant risk factor for patients
with candidemia due to C. albicans (35.2%, 25/71) compared to candidemia due to non-C. albicans spp
(13.2%, 22/167) (odds ratio (OR) 0.2792, 95% conﬁdence interval (CI) 0.144–0.5412; p < 0.001).
Compared to patients with candidemia due to non-C. guilliermondii spp, preterm birth with low birth
weight (OR 0.0887, 95% CI 0.0398–0.1977; p < 0.001), intravenous nutrition (OR 0.0662, 95% CI 0.0226–
0.1938), and surgery (OR 0.0662, 95% CI 0.0226–0.1938; p < 0.001) were signiﬁcant risk factors for
candidemia due to C. guilliermondii. Furthermore, compared to patients with candidemia due to C.
albicans, patients with candidemia due to C. guilliermondii had markedly higher rates of central venous
catheterization (85.9%, 61/71 vs. C. guilliermondii: 100%, 39/39; p = 0.013) and intravenous nutrition
(89.7%, 35/39 vs. C. albicans: 42.2%, 30/71; p < 0.001).
Conclusions: Candidemia due to C. albicans ranks ﬁrst in incidence, and candidemia due to C.
guilliermondii occurs in a signiﬁcant proportion of our hospitalized patients.
 2013 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious
Diseases. 
Contents lists available at ScienceDirect
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Candida species are important nosocomial pathogens that cause
substantial mortality and prolonged hospitalization. Although
Candida albicans accounts for the majority of candidemia cases,
non-C. albicans spp including Candida tropicalis, Candida glabrata,
Candida krusei, and Candida parapsilosis have emerged as* Corresponding author. Tel.: +86 021 25076700.
E-mail address: panshuming73@yahoo.cn (S. Pan).
1201-9712   2013 The Authors. Published by Elsevier Ltd on behalf of International S
http://dx.doi.org/10.1016/j.ijid.2013.11.011signiﬁcant pathogens of fungal bloodstream infections.1,2 In one
survey in the USA, C. glabrata was found to cause 3–35% of all
candidemia, followed by C. tropicalis, C. parapsilosis, and C. krusei.3
In a study of 102 non-neutropenic patients at a teaching hospital in
China, Wu et al. found that C. albicans accounted for 57.8% of all
cases, followed by C. tropicalis, C. parapsilosis, and C. glabrata.4
Similar ﬁndings have been reported for a cohort of hospitalized
patients in Turkey.5
Candida guilliermondii is an uncommon cause of candidemia in
much of the world and its incidence in the immunocompromised
host is also very low.6–10 In addition, there is scant data available
regarding the epidemiology of C. guilliermondii and risk factors for
candidemia due to C. guilliermondii. Anecdotal evidence suggests
that the incidence of C. guilliermondii may be on the rise in China,ociety for Infectious Diseases. Open access under CC BY-NC-SA license.
Table 1
The 3-year trend in candidemia and distribution of various Candida spp, 2009–2011a
Candida spp 2009 2010 2011 Total
C. albicans 31 25 15 71 (29.8)
C. tropicalis 3 12 12 27 (11.4)
C. parapsilosis 10 15 41 66 (27.7)
C. glabrata 3 5 3 11 (4.6)
C. guilliermondii 3 8 28 39 (16.4)
Others 11 6 7 24 (10.1)
Total 61 71 106 238 (100)
a Results are given as n (%).
Figure 1. The 3-year trends in candidemia cases due to Candida parapsilosis, Candida
guilliermondii, and other Candida spp at a metropolitan tertiary care hospital in
China.
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C. guilliermondii from six out of nine preterm infants in the
pediatric intensive care unit.11 C. guilliermondii infection also
causes concern among clinicians, as case reports have been
published describing echinocandin treatment failure due to
resistant isolates.12
A number of predisposing factors have been identiﬁed for
candidemia in hospitalized patients, including the administration
of intravenous nutrition, central venous catheterization, major
surgeries, and urinary catheterization.13 However, there is a
paucity of data regarding differences between C. albicans and non-
C. albicans bloodstream infections in hospitalized patients, and
between C. guilliermondii and non-C. guilliermondii bloodstream
infections in hospitalized patients. In this study we investigated
the epidemiology of candidemia in hospitalized patients at our
tertiary care facility and further analyzed risk factors for
candidemia due to C. albicans and non-C. albicans spp, and due
to C. guilliermondii and non-C. guilliermondii spp.
2. Patients and methods
2.1. Patients
We retrospectively reviewed the clinical records of all patients
with Candida bloodstream infections during their hospitalization
between January 1, 2009 and December 31, 2011 at our hospital, a
tertiary care comprehensive hospital with 1500 beds. Patients
were included if they had at least one positive blood culture for
Candida spp and signs or symptoms of infection. They were
excluded if they had received antifungal medication therapy before
admission or if they had experienced previous episodes of
candidemia before their admission to the hospital.
The study protocol was approved by the local institutional
review board at the authors’ afﬁliated institution. The institution
has implemented Good Clinical Practice. No informed consent was
obtained because of the retrospective nature of this study.
2.2. Patient evaluation
Demographic, clinical, laboratory, and microbiological data were
collected upon conﬁrmation of candidemia. Patient characteristics
and data extracted included age and sex, reason for hospital
admission, diseases predisposing to candidemia such as diabetes
mellitus and hematological diseases, and predisposing risk factors
such as surgery, administration of intravenous nutrition, central
venous catheterization (for at least 2 days), and urinary catheteri-
zation. In cases where a patient had more than one episode of
candidemia, the ﬁrst episode was used in the risk factor analysis. The
cases were classiﬁed according to the Candida spp responsible. For
microbiological studies, Candida spp were isolated from the blood
using the BacT/Alert 3D rapid culture and monitoring system and
were identiﬁed using the automated VITEK CC4 system (all
bioMe´rieux Vitek, France), as instructed by the manufacturer.
2.3. Statistical analysis
The mean, standard deviation (SD), maximum, and minimum
were used to describe quantitative data. Frequency was used to
describe categorical data. The statistical analysis was carried out
using SPSS version 13.0 statistical software (SPSS Inc., Chicago, IL,
USA). The Chi-square test or Fisher’s exact test was used to
evaluate categorical variables and the Student’s t-test to evaluate
continuous variables. Multivariate backwards stepwise logistic
regression analyses were performed to identify independent
variables associated with candidemia due to C. albicans and
non-C. albicans spp, C. guilliermondii and non-C. guilliermondii spp,as well as mortality. Potential risk factors were included in these
models if they were associated with the dependent variables in the
univariate analyses at a statistical level p < 0.05. A p-value less than
0.05 was considered statistically signiﬁcant in the multivariate
models to show an association between various potential risk
factors and the dependent variables.
3. Results
3.1. The distribution of Candida spp and patient demographic
characteristics and risk factors for candidemia
Two hundred forty-eight patients had Candida bloodstream
infections during the review period and 238 patients met the
inclusion criteria for the retrospective study. The incidence rate of
positive Candida cultures among the eligible patients was 5.4%. No
patients were immunocompromised or had received immunosup-
pressive therapy and no patients were neutropenic. The 3-year
trends of candidemia are shown in Table 1, along with the
distribution of various Candida spp. The most common cause of
candidemia was C. albicans (29.8%), followed by C. parapsilosis
(27.7%) and C. guilliermondii (16.4%). The number of candidemia
cases due to C. parapsilosis and C. guilliermondii increased noticeably,
while that of candidemia cases due to other Candida spp either
declined or remained stable over the 3-year period (Figure 1). Of
note, in 2009, C. parapsilosis and C. guilliermondii accounted for 16.4%
(10/61) and 4.9% (3/61) of the cases of candidemia, while C. albicans
accounted for approximately half of the cases (50.8%, 31/61). By
contrast, in 2011, C. parapsilosis accounted for nearly half of the
candidemia cases (48.8%, 41/84) and C. guilliermondii accounted for a
third of the cases (33.3%, 28/84), while the percentage of candidemia
due to C. albicans declined to 17.9% (15/84).
Patient demographics and underlying diseases and risk factors
for candidemia are shown in Table 2. The median age of the
Table 2
Patient demographic characteristics and risk factors for candidemia (N = 238)
Characteristics
Gender, male 142 (59.7)
Age, years, median (range) 44 (1–88)
Underlying disease, n (%)
Cerebrovascular disease 113 (47.5)
Cancer 10 (4.2)
Diabetes mellitus 47 (19.7)
Chronic pulmonary disease 1 (0.4)
Preterm infants with low birth weight 37 (15.5)
Intussusception 1 (0.4)
Hematologic disease 13 (5.5)
Underlying factors, n (%)
Surgery 60 (25.2)
Intravenous nutrition 108 (45.4)
Central venous catheterization 209 (87.8)
Urinary catheterization 186 (78.2)
Antifungal therapy, days, median (range) 10.6 (5–19)
30-day mortality, n (%) 49 (20.6)
Z. Wu et al. / International Journal of Infectious Diseases 22 (2014) 4–86patients was 44 years (range 1–88 years) and the majority (59.7%)
were male. Most patients (93.3%, 222/238) had an underlying
disease or risk factor(s). The most common underlying disease was
cerebrovascular disease (47.5%), followed by diabetes (19.7%) and
low birth weight preterm patients (15.5%). The great majority of
these patients had central venous catheterization (87.8%) and
urinary catheterization (78.2%). The patients had a median
duration of antifungal therapy of 10.6 days (range 5–19 days).
3.2. Risk factors for mortality of patients with candidemia
Forty-nine (20.6%) patients died within 30 days of hospitaliza-
tion. We further analyzed whether there were any differences in
demographic characteristics or risk factors and disease character-
istics between those patients who died and those who survived.
We found that among the underlying diseases, there was a
signiﬁcant difference in the rate of preterm infants with low birth
weight between those who died and those who survived (survived
19.0%, 36/189 vs. died 0%, 0/49; p = 0.002) (Table 3). In addition,
those patients who died had markedly higher rates of surgery
(98.0%, 48/49 vs. survivors 25.9%, 49/189; p < 0.001), intravenousTable 3
Multivariate analysis of risk factors associated with the mortality of patients with can
Characteristics Population data (N = 238) 
Survived
(n = 189)
Died
(n = 49)
Gender, male 110 32 
Age, years, median (range) 45.4 (1–88) 37.6 (1–
Underlying disease
Cancer 92 20 
Cerebrovascular disease 10 0 
Diabetes mellitus 39 8 
Chronic pulmonary diseases 1 0 
Preterm infants with low birth weight 36 0 
Intussusception 1 0 
Hematologic disease 12 1 
Underlying risk factors
Surgery 49 48 
Intravenous nutrition 36 49 
Central venous catheterization 160 49 
Urinary catheterization 145 41 
Identiﬁed species
Candida albicans 55 16 
Non-C. albicans spp 144 33
Antifungal therapy, days, median (range) 10.4 (5–19) 11.6 (6–
CI, conﬁdence interval; OR, odds ratio.nutrition (100%, 49/49 vs. survivors 19.0%, 36/189; p < 0.001), and
central venous catheterization (100%, 49/49 vs. survivors 84.7%,
160/189; p = 0.006). We further analyzed these risk factors by
multivariate analysis and found that candidemia due to C. albicans
or non-C. albicans spp had no inﬂuence on the 30-day mortality (p =
0.597). There was no signiﬁcant difference in the duration of
antifungal therapy between those who died and those who
survived.
3.3. Risk factors for candidemia due to C. guilliermondii
We further investigated risk factors for candidemia due to C.
guilliermondii and non-C. guilliermondii spp by multivariate
analysis. We found that among the underlying diseases, patients
with candidemia due to C. guilliermondii had a markedly higher
rate of preterm infants with low birth weight (51.3%, 20/39 vs. non-
C. guilliermondii spp: 8.5%, 17/199; p < 0.001) and a signiﬁcantly
lower rate of cancer (17.9%, 7/39; vs. non-C. guilliermondii: 53.3%,
106/199; p < 0.001) (Table 4). Multivariate analysis showed that,
compared to patients with candidemia due to C. guilliermondii,
patients with candidemia due to non-C. guilliermondii spp were
more likely to have cancer (odds ratio (OR) 5.2104, 95% conﬁdence
interval (CI) 2.1962–12.3618; p < 0.001), while patients with
candidemia due to C. guilliermondii were less likely to have a
history of preterm birth with low birth weight (OR 0.0887, 95% CI
0.0398–0.1977; p < 0.001). In addition, compared to patients with
candidemia due to C. guilliermondii, patients with candidemia due
to non-C. guilliermondii spp had markedly higher rates of surgery
(71.4%, 142/199 vs. C. guilliermondii: 41.0%, 16/39) (OR 3.5811, 95%
CI 1.7638–7.2711; p < 0.001) and urinary catheterization (83.9%,
167/199 vs. C. guilliermondii: 48.7%, 19/39) (OR 5.4934, 95% CI
2.6393–11.4338; p < 0.001). These patients had markedly lower
rates of intravenous nutrition (36.7%, 73/199 vs. C. guilliermondii:
89.7%, 35/39) (OR 0.0662, 95% CI 0.0226–0.1938; p < 0.001).
3.4. Risk factors for candidemia due to C. albicans
We also studied risk factors for candidemia due to C. albicans
and non-C. albicans spp by multivariate analysis. We found that
among the underlying diseases, patients with candidemia due to
non-C. albicans spp were less likely to have diabetes mellitusdidemia
Multivariate analysis
p-Value OR (95% CI) p-Value
0.416
86)
0.340
0.129
0.553
1
0.002 3.35  109 <0.001
1
0.314
<0.001
<0.001 0.097 (0.038–0.246)
0.006 1.888 (0.817–4.36)
0.338 1.840 (0.566–5.98)
0.597
18) 0.238
Table 4
Multivariate analysis of risk factors for candidemia due to Candida guilliermondii
Characteristics Population data (N = 238)
C. guilliermondii C. non-guilliermondii OR (95% CI) p-Value
(n = 39) (n = 199)
Gender, male 22 120 1.1738 (0.5866–2.3489) 0.721
Age, years, median (range) 17.5 (1–78) 49.2 (1–88)
Underlying disease
Cancer 7 106 5.2104 (2.1962–12.3618) <0.001
Cerebrovascular diseases 1 9 1.8 (0.2215–14.6284) 0.705
Diabetes mellitus 7 40 1.15 (0.4731–2.7957) 0.823
Chronic pulmonary diseases 0 1 1.197 (1.1312–1.2666) 1
Preterm infants with low birth weight 20 17 0.0887 (0.0398–0.1977) <0.001
Intussusception 1 0 None 0.164
Hematologic disease 1 12 2.4385 (0.3078–19.3176) 0.484
Underlying risk factors
Surgery 16 142 3.5811 (1.7638–7.2711) <0.001
Intravenous nutrition 35 73 0.0662 (0.0226–0.1938) <0.001
Central venous catheterization 39 170 0.8134 (0.7623–0.868) 0.013
Urinary catheterization 19 167 5.4934 (2.6393–11.4338) <0.001
CI, conﬁdence interval; OR, odds ratio.
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albicans (35.2%, 25/71) (OR 0.2792, 95% CI 0.144–0.5412; p <
0.001), while other underlying diseases or risk factors showed no
correlation with candidemia due to C. albicans (Table 5).
3.5. Risk factors for candidemia due to C. albicans vs. C.
guilliermondii
We further investigated underlying diseases and risk factors for
candidemia due to C. albicans and C. guilliermondii. We found that
among the underlying diseases, patients with candidemia due to C.
albicans had a signiﬁcantly higher incidence of cancer (50.7%, 36/71
vs. C. guilliermondii: 17.9%, 7/39; p < 0.001), while patients with
candidemia due to C. guilliermondii had a markedly higher rate of
preterm infants with low birth weight (51.3%, 20/39 vs. C. albicans:
8.5%, 6/71; p < 0.001) (Table 6). Furthermore, patients with
candidemia due to C. albicans had markedly higher rates of surgery
(67.6%, 48/71 vs. C. guilliermondii: 41.0%, 16/39; p = 0.009) and
urinary catheterization (81.7%, 58/71 vs. C. guilliermondii: 48.7%,
19/39; p < 0.001), while patients with candidemia due to C.
guilliermondii had markedly higher rates of central venous
catheterization (100%, 39/39 vs. C. albicans: 85.9%, 61/71; p =
0.013) and intravenous nutrition (89.7%, 35/39 vs. C. albicans:
42.3%, 30/71; p < 0.001).Table 5
Multivariate analysis of risk factors for candidemia due to Candida albicans
Characteristics Population data (N = 238)
C. albicans (n = 71) C.
Gender, male 41 10
Age, years, median (range) 50.2 (1–87) 4
Underlying disease
Cancer 36 7
Cerebrovascular disease 1 
Diabetes mellitus 25 2
Chronic pulmonary diseases 0 
Preterm infants with low birth weight 6 3
Intussusception 1 
Hematologic disease 4 
Underlying risk factors
Surgery 48 11
Intravenous nutrition 30 7
Central venous catheterization 61 14
Urinary catheterization 58 12
CI, conﬁdence interval; OR, odds ratio.4. Discussion
Candidemia remains a signiﬁcant concern for hospitalized
patients, especially those in the intensive care units and the
immunocompromised.14 Clinically, we have seen an increasing
number of patients with candidemia due to C. guilliermondii at our
tertiary care center (unpublished data). In the current study, we
found that candidemia was seen in 5.4% of hospitalized patients
during the review period; approximately 30% of the cases were due
to C. albicans and another 30% due to C. parapsilosis. A higher rate of
candidemia due to C. albicans (57.8%) was reported by Wu et al.4 in
a study of 102 non-neutropenic patients. The appearance of C.
parapsilosis as the most frequent non-C. albicans spp (27.7% of all
isolates) is consistent with the pattern seen in Europe,15 where this
species accounts for approximately 20% of candidemia, ranking
only behind C. albicans in incidence. Of note, we observed a
changing pattern of candidemia among our hospitalized patients:
the proportion of candidemia due to C. albicans declined, while the
proportion of candidemia due to C. parapsilosis and C. guilliermondii
increased over the 3-year period. The latter two species together
accounted for more than 80% of all candidemia cases in 2011. This
changing pattern, if also true for other similar tertiary care
institutions in China, is of signiﬁcance for public health and
therapeutic decision-making. non-albicans (n = 167) OR (95% CI) p-Value
1 1.1197 (0.6371–1.968) 0.772
1.2 (1–88)
7 0.8318 (0.4771–1.4503) 0.571
9 3.9873 (0.4956–32.0797) 0.229
2 0.2792 (0.144–0.5412) <0.001
1 1
1 2.4694 (0.9813–6.2136) 0.052
0 0.298
9 0.9541 (0.284–3.2059) 1
0 0.9247 (0.512–1.67) 0.881
8 1.1978 (0.6838–2.0979) 0.571
8 1.277 (0.5614–2.9044) 0.665
8 0.7356 (0.3652–1.4817) 0.400
Table 6
Risk factors for candidemia due to Candida albicans vs. Candida guilliermondii
Characteristics C. guilliermondii
(n = 39)
C. albicans
(n = 71)
p-Value
Gender, male 22 41 1
Age, years, median (range) 17.5 (1–78) 50.2 (1–87)
Underlying disease
Cancer 7 36 0.001
Cerebrovascular disease 1 1 1
Diabetes mellitus 7 25 0.079
Chronic pulmonary diseases 0 0 1
Preterm infants with low
birth weight
20 6 <0.001
Intussusception 1 1 1
Hematologic disease 1 4 0.654
Underlying risk factors
Surgery 16 48 0.009
Intravenous nutrition 35 30 <0.001
Central venous catheterization 39 61 0.013
Urinary catheterization 19 58 <0.001
Z. Wu et al. / International Journal of Infectious Diseases 22 (2014) 4–88Despite many methods being available for the identiﬁcation of
Candida spp, the currently available methods are not able to
discriminate subspecies, and molecular typing methods such as
whole genome sequencing, a highly discriminatory typing method,
are required to identify sources of transmission or outbreaks.16
Currently, there is scant literature on the epidemiology and risk
factors for C. guilliermondii.17 Of note in this study is that C.
guilliermondii was found in a signiﬁcant proportion (16.4%) of our
hospitalized patients. C. guilliermondii is an uncommon cause of
candidemia, even in immunocompromised hosts.6–8,10,18,19 Various
risk factors have been identiﬁed for candidemia due to C. albicans,
such as the administration of intravenous nutrition, central venous
catheterization, major surgeries, and urinary catheterization.12
However, there is scant literature on the differences in risk factors
between C. guilliermondii and non-C. guilliermondii spp. We found
that compared to non-C. guilliermondii spp, C. guilliermondii was
strongly associated with preterm infants with low birth weights and
intravenous nutrition. Our report contains the largest number of
cases of candidemia due to C. guilliermondii so far. Our ﬁndings show
that physicians should look beyond the usual suspects (C. albicans) to
include non-C. albicans in their consideration of causes of
candidemia. As these data are from a single tertiary care center in
China, it remains unknown whether the high rate of C. guilliermondii
also holds true at other tertiary care medical institutions in China,
the answer for which needs further investigation. As the methods we
used in the current study did not allow us to perform highly
discriminatory typing of the Candida spp, it also remains unknown
whether the high rate of C. guilliermondii infection at our hospital
was due to a single or multiple sources of infection. The high rate of C.
guilliermondii in preterm infants is consistent with the anecdotal
ﬁnding of Ma et al. who isolated this organism from six out of nine
preterm infants in the pediatric intensive care unit.11
The results of this study provide important information
regarding the distribution of Candida spp in patients with
candidemia in China for which there is a paucity of data regarding
the epidemiology and risk factors of these species. These results
should be helpful to other physicians in China. They also raise new
questions, such as the reason for the increased rate of C.
guilliermondii, which needs to be further investigated.Acknowledgements
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